SCHEMBL226537

SCHEMBL226537

CCOC(=O)[CH]c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
CTDSP1 Q9GZU7 1/20 0.49
TSHR P16473 1/20 0.48
MAPT P10636 6/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
RAB9A P51151 4/20 0.46
LMNA P02545 3/20 0.46
MDM2 Q00987 3/20 0.46
NPC1 O15118 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MAPK1 P28482 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3938923 0.85 LMNA (0.55) MEN1KMT2ATSHRLMNAL3MBTL1
SCHEMBL5675140 0.82 TSHR (0.54) MEN1KMT2ATSHRLMNAL3MBTL1
SCHEMBL16115071 0.81 MAPT (0.60) MEN1KMT2AMAPTCA12CA1
Ethyl Cinnamate SCHEMBL112445 0.81 CA12 (0.72) MEN1KMT2AMAPTCA12CA1
Ethyl Cinnamate SCHEMBL112446 0.81 CA12 (0.72) MEN1KMT2AMAPTCA12CA1
Ethyl Cinnamate SCHEMBL1866942 0.81 CA12 (0.72) MEN1KMT2AMAPTCA12CA1
SCHEMBL11233379 0.81 CA12 (0.49) MEN1KMT2ATSHRMAPTCA12
Ethyl Cinnamate SCHEMBL12001792 0.81 CA12 (0.72) MEN1KMT2AMAPTCA12CA1
SCHEMBL9275866 0.80 TSHR (0.56) TSHRRAB9ALMNANPC1L3MBTL1
Benzaldehyde SCHEMBL28616809 0.79 KMT2A (0.54) MEN1KMT2ACTDSP1TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114716386-A Novel exosome inhibitor and preparation method thereof 北京和理咨询有限公司 2022-07-08 CN claimed
CN-110612119-A Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents 西雅图儿童医院(DBA西雅图儿童研究所) 2019-12-24 CN claimed
US-9809822-B2 Triptolide derivatives and preparation method and use thereof HONG KONG BAPTIST UNIVERSITY (HK) 2017-11-07 US claimed
US-20160362691-A1 TRIPTOLIDE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF HONG KONG BAPTIST UNIVERSITY (HK) 2016-12-15 US claimed
EP-3051946-A1 USE OF SUBSTITUTED DIHYDRO-OXINDOLYL SULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS Bayer CropScience Aktiengesellschaft (DE) 2016-08-10 EP claimed
US-9340498-B2 Raft polymerisation COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESERACH ORGANISATION (AU) 2016-05-17 US claimed
WO-2015049351-A1 USE OF SUBSTITUTED DIHYDRO-OXINDOLYL SULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS BAYER CROPSCIENCE AG (DE) 2015-04-09 WO claimed
CN-103214431-A 2,3-dihydrobenzazapine*compound or its salt and its medical application UNIV FUDAN 2013-07-24 CN claimed
US-7932264-B2 Sinomenine derivatives and preparation and uses thereof NATUREMED GROUP CORPORATION (US) 2011-04-26 US claimed
EP-1194428-B1 HETEROARYL PROTEASE INHIBITORS AND DIAGNOSTIC IMAGING AGENTS DIMENSIONAL PHARM INC (US) 2003-09-17 EP claimed
WO-1992012151-A1 N-ALKYL QUINUCLIDINIUM SALTS AS SUBSTANCE P ANTAGONISTS PFIZER INC. (US) 1992-07-23 WO claimed
WO-1992000951-A1 PHARMACEUTICAL COMPOSITIONS NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1992-01-23 WO claimed
WO-1991000854-A1 N,N'-DICARBOXYMETHYL, N,N'-DIAMINOCARBONYLMETHYL-DIAMINOALKANE DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1991-01-24 WO claimed
EP-0408384-A1 N,N'-dicarboxymethyl, N,N'-dicarbamoylmethyl diaminoalkane derivatives and their use in pharmaceutical compositions. BTG INTERNATIONAL LIMITED (GB) 1991-01-16 EP claimed
EP-0197752-B1 PHARMACEUTICAL COMPOSITIONS NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1990-09-12 EP claimed
US-4902714-A N,N'-DIPROPARGYLOXYCARBONYLMETHYL-N,N'-DIAMINOCARBONYLMETHYL -1,2-DIAMINOPROPANE NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1990-02-20 US claimed
US-4755619-A Pharmaceutical compositions NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1988-07-05 US claimed
EP-0197752-A2 Pharmaceutical compositions NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1986-10-15 EP claimed
EP-0051877-B1 CARBAMOYLOXYISOOXAZOLE DERIVATIVES, THEIR PREPARATION AND INSECTICIDAL COMPOSITIONS CONTAINING THEM SANKYO COMPANY LIMITED (JP) 1984-09-05 EP claimed
US-3933800-A O-SUBSTITUTED OXIMES, MICROBIOCIDES GRUPPO LEPETIT S.P.A. (IT) 1976-01-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160362691-A1 TRIPTOLIDE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF TPD52L2, TRDMT1, MCTS1 MEN1 1435/4885KMT2A 2967/4885CTDSP1 1726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.